GRFS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Grifols SA (GRFS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial growth in the latest quarter and has a potential IPO catalyst, the technical indicators are bearish, hedge funds are selling heavily, and analysts have downgraded the stock with reduced price targets. Additionally, the options data suggests a cautious trading sentiment. Given the investor's impatience and unwillingness to wait for optimal entry points, holding off on this stock for now is advisable.
The technical indicators for GRFS are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 32.066, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 7.754 and support at 7.483.
Grifols is evaluating a potential U.S. IPO for its biopharma business, which could provide new capital sources and enhance financial independence. Revenue and net income showed significant YoY growth in Q4 2025.
Gross margin dropped by -10.65% YoY in Q4 2025.
In Q4 2025, Grifols reported a 9.47% YoY revenue increase to $2.31 billion, a 55.49% YoY net income increase to $114.37 million, and a 54.55% YoY EPS increase to $0.17. However, gross margin declined by -10.65% YoY to 34.66%.
Analysts have downgraded the stock recently. Deutsche Bank lowered the price target from EUR 12 to EUR 11, maintaining a Hold rating. Morgan Stanley downgraded the stock to Equal Weight from Overweight, reducing the price target from EUR 14 to EUR 11.
